Beta Bionics (NASDAQ:BBNX) Price Target Cut to $14.00 by Analysts at Robert W. Baird

Beta Bionics (NASDAQ:BBNX) had its price objective cut by Robert W. Baird from $28.00 to $14.00 in a report issued on Wednesday, Marketbeat Ratings reports. They currently have a neutral rating on the stock.

A number of other research analysts have also recently commented on the company. Truist Financial dropped their price target on Beta Bionics from $37.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. TD Cowen started coverage on shares of Beta Bionics in a report on Monday, January 26th. They issued a “hold” rating and a $17.00 price objective for the company. UBS Group raised shares of Beta Bionics to a “strong-buy” rating in a report on Monday, February 9th. The Goldman Sachs Group reiterated a “buy” rating and set a $25.00 price target on shares of Beta Bionics in a report on Thursday, January 15th. Finally, Wall Street Zen lowered Beta Bionics from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $23.33.

Beta Bionics Stock Performance

Shares of BBNX opened at $13.61 on Wednesday. Beta Bionics has a 52-week low of $8.89 and a 52-week high of $32.71. The firm has a market cap of $599.25 million and a price-to-earnings ratio of -6.98. The business’s fifty day moving average is $21.78 and its 200-day moving average is $22.53.

Beta Bionics (NASDAQ:BBNX) last released its earnings results on Tuesday, February 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.12. Beta Bionics had a negative return on equity of 20.02% and a negative net margin of 73.02%.The firm had revenue of $32.12 million for the quarter.

Insider Activity

In other Beta Bionics news, CFO Stephen Feider sold 20,000 shares of the firm’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $29.53, for a total value of $590,600.00. Following the completion of the sale, the chief financial officer directly owned 42,614 shares in the company, valued at approximately $1,258,391.42. This trade represents a 31.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mike Mensinger sold 2,200 shares of the company’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $30.10, for a total transaction of $66,220.00. Following the transaction, the insider owned 80,752 shares in the company, valued at $2,430,635.20. This represents a 2.65% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 32,490 shares of company stock worth $960,835.

Hedge Funds Weigh In On Beta Bionics

A number of institutional investors have recently modified their holdings of BBNX. GPS Wealth Strategies Group LLC increased its stake in Beta Bionics by 45.0% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Beta Bionics by 0.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 331,623 shares of the company’s stock valued at $10,105,000 after purchasing an additional 931 shares during the last quarter. Deutsche Bank AG lifted its holdings in shares of Beta Bionics by 3.4% in the fourth quarter. Deutsche Bank AG now owns 39,300 shares of the company’s stock valued at $1,197,000 after purchasing an additional 1,296 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Beta Bionics by 203.6% during the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after buying an additional 1,594 shares during the last quarter. Finally, Summit Securities Group LLC bought a new stake in Beta Bionics during the fourth quarter worth $52,000.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Q4 & full‑year results showed strong top‑line growth and an earnings beat: Q4 net sales $32.1M (57% YoY), FY2025 sales $100.3M (up 54%), and EPS beat consensus (loss per share of $0.30 vs. estimate of $0.42). Management guided 2026 revenue to ~$130M–$135M, above consensus, and reported $264.7M in cash — fundamentals that support longer‑term growth expectations. Company Press Release
• Positive Sentiment: Commercial traction and product pipeline progress: installed base grew to ~35k users (up 129% YoY), PBP channel sales surged, and the company completed a first‑in‑human Phase 2a bihormonal feasibility trial — all supportive of sustained revenue expansion and pipeline value. QuiverQuant Summary
• Neutral Sentiment: Earnings call/transcripts and slide deck are available for investors to review details on channel mix, margins, and clinical plans — useful for modeling but not immediate catalysts. Earnings Call Transcript
• Neutral Sentiment: Some analysts are taking a cautious stance but not unanimous: TD Cowen maintained a Hold with a $16 target — a signal that the street is mixed on near‑term prescription/reimbursement headwinds vs. growth. TipRanks Note
• Negative Sentiment: Analyst downgrade/target cut: Robert W. Baird lowered its price target from $28 to $14 and moved to Neutral — a headline likely contributing to today’s sell‑side pressure and reduced upside in near term. The Fly: Baird Cuts Target
• Negative Sentiment: Investor litigation alerts from multiple law firms (Faruqi & Faruqi; Pomerantz) introduce headline risk and potential legal overhang that can pressure the stock and increase volatility. Faruqi & Faruqi Notice Pomerantz Alert
• Negative Sentiment: Profitability remains a concern: despite revenue growth, the company reported sizable operating losses and negative adjusted EBITDA — a reminder that revenue growth is not yet translating into GAAP profitability. Zacks Coverage

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.